Efficacy, Safety, and Tolerability of Laquinimod in Relapsing Remitting Multiple Sclerosis
- Study Title
- The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
- Teva Identifier
- LAQ-MS-305 | 2012-003647-30
- ClinicalTrials.gov Identifier
- NCT01707992
- Study Status
- Completed
- Trial Condition(s)
- Multiple Sclerosis
- Interventions
- Drug: Laquinimod | Drug: Placebo
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult
- Age Range
- 18 Years to 55 Years
- Trial Duration
- February 20, 2013 - July 4, 2017
- Phase
- Phase 3
